T
21.34
0.25 (1.19%)
| Previous Close | 21.09 |
| Open | 21.13 |
| Volume | 35,937 |
| Avg. Volume (3M) | 211,211 |
| Market Cap | 398,471,168 |
| Price / Book | 1.41 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 0.87% |
| Current Ratio (MRQ) | 22.92 |
| Operating Cash Flow (TTM) | -62.89 M |
| Levered Free Cash Flow (TTM) | -69.56 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -41.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Tectonic Therapeutic, Inc. | Bearish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 38.29% |
| % Held by Institutions | 59.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 31 Mar 2025 | 302,953 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 87.00 (LifeSci Capital, 307.69%) | Buy |
| Median | 80.50 (277.23%) | |
| Low | 64.00 (Truist Securities, 199.91%) | Buy |
| Average | 78.00 (265.51%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 22.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 21 Jul 2025 | 64.00 (199.91%) | Buy | 21.92 |
| Raymond James | 11 Jun 2025 | 76.00 (256.14%) | Buy | 23.50 |
| LifeSci Capital | 06 Jun 2025 | 87.00 (307.69%) | Buy | 23.06 |
| Mizuho | 15 May 2025 | 85.00 (298.31%) | Buy | 20.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Jun 2025 | Announcement | Tectonic Therapeutic Joins Russell 3000® Index |
| 17 May 2025 | Announcement | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 |
| 08 May 2025 | Announcement | Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights |
| 07 May 2025 | Announcement | Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |